BREAKING NEWS
GMP Manufacturing
Has Completed!
We are very pleased to announce an important milestone - GMP manufacturing has finished at our CDMO STC Biologics Inc for CPI-601 our recombinant enzyme replacement therapy for Batten Disease CLN1. Analytical testing is ongoing and then we have drug product filling. The next stage is a clinical trial.
There is currently no FDA approved treatment for this ultra-rare fatal disease. CPI-601 development has been funded by the National Institute of Neurological Disorders and Stroke (NINDS). If you are interested in partnering with us please get in touch.
View Pipeline
OUR MISSION
Transforming Chemistry,
Enriching Lives
We use real drug discovery intelligence alongside artificial intelligence to develop clinical candidates for rare, neglected and unmet therapeutic needs.
Our pipeline reflects years of dedicated research, innovative breakthroughs, and a commitment to bringing life-changing treatments to those who need them most.
View Pipeline
OUR TOOLS
Innovative Solutions To Complex Challenges
Whether you’re looking to predict toxicity, visualize molecular data, or build machine learning models, our tools are designed to meet your unique needs.
Not sure which tool is right for you?
Take our short assessment to find the perfect solution for your professional goals.
OUR PARTNERS
Drive Success Through Collaboration
Breakthroughs happen when expertise meets opportunity. At the core of our success lies a commitment to collaboration, partnering with innovators, organizations, and researchers who share our vision for advancing science and transforming lives.
Whether through licensing agreements, strategic partnerships, or tailored contracting solutions, we build relationships that deliver meaningful impact.
Partner With UsWHO WE ARE
Innovators in Machine Learning and ADME/Tox
Collaborations Pharmaceuticals, Inc.® is a privately owned company that performs research and development on innovative therapeutics for multiple rare and neglected infectious diseases. We develop and apply our artificial intelligence (AI) software to aid in drug discovery and toxicology assessment as well as to identify and translate early preclinical to clinical stage assets. Our software can also be used to design new molecules with desired properties. This software can be used by pharmaceutical, consumer product, as well as other companies that require chemistry.
HOW WE’RE DIFFERENT
Scientists Focused On Doing Science
Collaborations Pharmaceuticals, Inc.® is a privately owned company that performs research and development. We can apply our artificial intelligence (AI) software to aid your company in solving challenges you may encounter. Our software can be used by pharmaceutical, agrochemical, consumer product companies and anyone interested in chemistry.
CONTACT USMachine Learning & Generative Design Tools
SEE ALL TOOLS
A platform for the generative design of molecules to create new intellectual property
SEE DETAILS
A suite of tools to curate structure activity data, then build and validate machine learning models
SEE DETAILS
Thousands of machine learning models to help prioritize new uses and off target effects of molecules
SEE DETAILS
A suite of ADME and toxicology machine learning models with optional read across module
SEE DETAILS
Human uptake and efflux transporter machine learning models
SEE DETAILS
Molecule preparation, autocuration and data visualization tools
SEE DETAILS
Acetylcholinesterase machine learning models for multiple species
SEE DETAILS
A comprehensive database of macrolactones and associated biological data
SEE DETAILS
Prediction of the UV-VIS spectra for a molecule from structure alone
SEE DETAILS
A robust chemical inventory tracking software with fine-grained location tracking, advanced querying options, and cross-platform support.
SEE DETAILSFEATURED PUBLICATION
Enzyme replacement therapy for CLN1 batten disease that crosses the blood-brain-barrier
Renuka Raman, Ben Horst, Zahra Shahrohk, Nader Hatambeygi, Marayam Zare, Magdalena Leszczynieka, Joshua S Harris, William A Banks, Kim M Hansen, Michelle A Erickson, Sean Ekins. 2026 Mar; DOI: 10.1016/j.ymgme.2026.109733
CLN1 Batten disease is caused by mutations in the CLN1 gene which codes for the lysosomal enzyme palmitoyl-protein thioesterase-1 (PPT1). Disease progression is marked by intellectual and motor deterioration, seizures, vision loss, and early mortality. There are no approved treatments for this severe pediatric condition. We describe the development and characterization of recombinant human PPT1 (rhPPT1) suitable for use as a clinical enzyme replacement therapy in CLN1 Batten patients. rhPPT1 displays similar mannose-6-phosphate receptor (M6PR)-dependent uptake kinetics in neuronal cell lines from human, rat and non-human primate but not in mouse cells. [...]
READ MORE>150
9
3
2
12
7
WHAT WE DO
No Disease Is Too Small
We apply our machine learning and drug discovery expertise to a wide array of projects both internally and with collaborators. Our toxicology models and read across software could assist your companies sustainable chemistry goals and help you in regulatory filings. We have developed new approaches which can be used to rapidly predict molecular properties for massive DNA-encoded libraries or predict properties for PROTACS. In the process of our work we have raised awareness of the potential for dual use of these AI technologies and therefore have expertise for such evaluations which has caught the attention of government agencies.